PSTX
Income statement / Annual
Last year (2023), Poseida Therapeutics, Inc.'s total revenue was $64.70 M,
a decrease of 50.37% from the previous year.
In 2023, Poseida Therapeutics, Inc.'s net income was -$123.43 M.
See Poseida Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$64.70 M |
$130.36 M |
$31,238.00 |
$0.00 |
$0.00 |
$0.00 |
$2.99 M |
$9.77 M |
| Cost of Revenue |
$156.77 M
|
$5.17 M
|
$4.55 M
|
$2.59 M
|
$1.19 M
|
$689,000.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$92.07 M
|
$125.19 M
|
-$4.52 M
|
-$2.59 M
|
-$1.19 M
|
-$689,000.00
|
$2.99 M
|
$9.77 M
|
| Gross Profit Ratio |
-1.42
|
0.96
|
-144.72
|
0
|
0
|
0
|
1
|
1
|
| Research and Development Expenses |
$156.77 M
|
$152.90 M
|
$136,734.00
|
$103,520.00
|
$60.39 M
|
$30.88 M
|
$19.10 M
|
$9.86 M
|
| General & Administrative Expenses |
$37.44 M
|
$37.54 M
|
$35,915.00
|
$23,029.00
|
$18.46 M
|
$9.67 M
|
$5.48 M
|
$5.35 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$220,000.00
|
| Selling, General & Administrative Expenses |
$37.44 M
|
$37.54 M
|
$35,915.00
|
$23,029.00
|
$18.46 M
|
$9.67 M
|
$5.48 M
|
$5.13 M
|
| Other Expenses |
$0.00
|
$2.86 M
|
$19,795.00
|
$280.00
|
$2.56 M
|
-$821,000.00
|
$37,000.00
|
$0.00
|
| Operating Expenses |
$194.21 M
|
$190.44 M
|
$172,649.00
|
$126,549.00
|
$78.85 M
|
$40.56 M
|
$24.58 M
|
$15.00 M
|
| Cost And Expenses |
$179.36 M
|
$190.44 M
|
$172,649.00
|
$126,549.00
|
$78.85 M
|
$40.56 M
|
$24.58 M
|
$15.22 M
|
| Interest Income |
$0.00
|
$6.37 M
|
$3.36 M
|
$3.51 M
|
$1.55 M
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$8.67 M
|
$6.37 M
|
$3,358.00
|
$3,506.00
|
$3.55 M
|
$1.80 M
|
$558,000.00
|
$0.00
|
| Depreciation & Amortization |
$5.61 M
|
$5.17 M
|
$4.55 M
|
$2.59 M
|
$1.19 M
|
$689,000.00
|
$676,000.00
|
$220,000.00
|
| EBITDA |
-$109.04 M |
-$54.77 M |
-$117.06 M |
-$145.48 M |
-$91.68 M |
-$45.12 M |
-$20.88 M |
-$5.12 M |
| EBITDA Ratio |
-1.69
|
-0.42
|
-3747.49
|
0
|
0
|
0
|
-6.99
|
-0.52
|
| Operating Income Ratio |
-2
|
-0.46
|
-4.53
|
0
|
0
|
0
|
-6.59
|
-0.56
|
| Total Other Income/Expenses Net |
$6.18 M
|
-$3.51 M
|
$16.44 M
|
-$129.65 M
|
-$7.68 M
|
-$2.62 M
|
$1.40 M
|
$109,000.00
|
| Income Before Tax |
-$123.32 M
|
-$63.46 M
|
-$124,974.00
|
-$129,775.00
|
-$86.53 M
|
-$44.61 M
|
-$20.19 M
|
-$5.34 M
|
| Income Before Tax Ratio |
-1.91
|
-0.49
|
-4
|
0
|
0
|
0
|
-6.76
|
-0.55
|
| Income Tax Expense |
$107,000.00
|
$544,000.00
|
-$4.53 M
|
-$2.58 M
|
$6.11 M
|
-$202,000.00
|
-$527,000.00
|
-$765,000.00
|
| Net Income |
-$123.43 M
|
-$64.00 M
|
$4.40 M
|
$2.45 M
|
-$92.64 M
|
-$44.40 M
|
-$19.66 M
|
-$4.58 M
|
| Net Income Ratio |
-1.91
|
-0.49
|
140.98
|
0
|
0
|
0
|
-6.59
|
-0.47
|
| EPS |
-1.37 |
-0.89 |
0.0708 |
0.0681 |
-2.33 |
-1.24 |
-0.49 |
-0.0771 |
| EPS Diluted |
-1.37 |
-0.89 |
0.0708 |
0.0681 |
-2.33 |
-1.24 |
-0.49 |
-0.0771 |
| Weighted Average Shares Out |
$90.19 M
|
$71.91 M
|
$62.18 M
|
$36.00 M
|
$39.73 M
|
$35.93 M
|
$39.73 M
|
$59.32 M
|
| Weighted Average Shares Out Diluted |
$90.19 M
|
$71.95 M
|
$62.24 M
|
$36.00 M
|
$39.73 M
|
$35.93 M
|
$39.73 M
|
$59.32 M
|
| Link |
|
|
|
|
|
|
|
|
